NewAmsterdam Pharma (NAMS) FCF Margin (2023 - 2026)
NewAmsterdam Pharma's (NAMS) quarterly FCF Margin came in at 1007.96% in Q1 2026, up 21716.0% year-on-year from N/an in Q1 2025, and up 99.21% quarter-over-quarter from 128046.88% in Q4 2025.
NewAmsterdam Pharma (NAMS) FCF Margin (2023 - 2026) Analysis & Trends
NewAmsterdam Pharma has disclosed FCF Margin across 4 years of filings, most recently posting 1007.96% for Q1 2026.
- FCF Margin for Q1 2026 came in at 1007.96%, up 21716.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 630.12% (down 33158.0% YoY), and the FY2025 annual result was 657.82%, down 30833.0% from the prior year.
- FCF Margin came in at 1007.96% for Q1 2026 at NewAmsterdam Pharma, up from 128046.88% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 43.2% in Q3 2024 to a low of 128046.88% in Q4 2025.
- The 4-year median for FCF Margin is 1411.35% (2023), against an average of 12719.25%.
- Across the five-year window, FCF Margin jumped 382569 bps in 2024 and plunged 12775339 bps in 2025, its largest moves.
- NewAmsterdam Pharma's FCF Margin stood at 4119.18% in 2023, then soared by 93 bps to 293.49% in 2024, then slumped by 43530 bps to 128046.88% in 2025, then soared by 99 bps to 1007.96% in 2026.
- The last three FCF Margin figures came in at 1007.96% (Q1 2026), 128046.88% (Q4 2025), and 9428.45% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | NewAmsterdam Pharma | 3.63 Bn | 3.63 Bn | - | -1,007.96% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,007.96% |
| Dec 31, 2025 | -128,046.88% |
| Sep 30, 2025 | -9,428.45% |
| Jun 30, 2025 | -197.23% |
| Mar 31, 2025 | -1,225.12% |
| Dec 31, 2024 | -293.49% |
| Sep 30, 2024 | -43.20% |
| Jun 30, 2024 | -2,377.71% |
| Mar 31, 2024 | -3,924.84% |
| Dec 31, 2023 | -4,119.18% |
| Sep 30, 2023 | -1,597.59% |
| Mar 31, 2023 | -369.34% |